keyword
MENU ▼
Read by QxMD icon Read
search

Vortioxetine

keyword
https://www.readbyqxmd.com/read/28881483/meta-analysis-risk-of-hyperhidrosis-with-second-generation-antidepressants
#1
Chad Beyer, Kiley Cappetta, Jessica A Johnson, Michael H Bloch
BACKGROUND: Our goal was to quantify the risk of hyperhidrosis associated with commonly used antidepressant agents and examine the impact of medication class, pharmacodynamics, and dose on risk of hyperhidrosis. METHODS: We conducted a PubMed search to identify all double-blind, randomized, placebo-controlled trials examining the efficacy of second-generation antidepressant medications in the treatment of adults with a depressive disorder, anxiety disorders, or obsessive-compulsive disorder...
September 7, 2017: Depression and Anxiety
https://www.readbyqxmd.com/read/28874391/%C3%A2-vortioxetine-for-acute-depression-in-adults
#2
(no author information available yet)
No abstract text is available yet for this article.
September 5, 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28858412/a-randomized-double-blind-placebo-controlled-8-week-trial-of-the-efficacy-safety-and-tolerability-of-5-10-and-20-mg-day-vortioxetine-in-adults-with-major-depressive-disorder
#3
Akira Nishimura, Yutaka Aritomi, Kiyofumi Sasai, Tadayuki Kitagawa, Atul R Mahableshwarkar
AIM: This study assessed the efficacy and safety of vortioxetine in adults with major depressive disorder. METHODS: In this double-blind, placebo-controlled study, 600 patients with major depressive disorder were randomly assigned (1:1:1:1) to receive vortioxetine 5, 10, or 20 mg, or placebo once daily for 8 weeks. The primary endpoint was change from baseline in Montgomery-Åsberg Depression Rating Scale total score at week 8, evaluated by the last observation carried forward method...
August 31, 2017: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/28811018/direct-coupling-of-electromembrane-extraction-to-mass-spectrometry-advancing-the-probe-functionality-toward-measurements-of-zwitterionic-drug-metabolites
#4
Torstein Kige Rye, David Fuchs, Stig Pedersen-Bjergaard, Nickolaj Jacob Petersen
A triple-flow electromembrane extraction (EME) probe was developed and coupled directly to electrospray-ionization mass spectrometry (ESI-MS). Metabolic reaction mixtures (pH 7.4) containing drug substances and related metabolites were continuously drawn (20 μL/min) into the EME probe in one flow channel, and mixed inside the probe with 7.5 μL min(-1) of 1 M formic acid as make-up flow from a second flow channel. Following this acidification, the drug substances and their related metabolites were continuously extracted by EME at 400 V, across a supported liquid membrane (SLM) comprising 2-nitrophenyl octyl ether (and for some experiments containing 30% triphenyl phosphate (TPP)), and into 20 μL min(-1) of formic acid as acceptor phase, which was introduced through a third flow channel...
August 29, 2017: Analytica Chimica Acta
https://www.readbyqxmd.com/read/28802861/contrasting-effects-of-vortioxetine-and-paroxetine-on-pineal-gland-biochemistry-in-a-tryptophan-depletion-model-of-depression-in-female-rats
#5
M Franklin, N Hlavacova, Y Li, I Bermudez, A Csanova, C Sanchez, D Jezova
We studied the effects of the multi-modal antidepressant, vortioxetine and the SSRI, paroxetine on pineal melatonin and monoamine synthesis in a sub-chronic tryptophan (TRP) depletion model of depression based on a low TRP diet. Female Sprague-Dawley rats were randomised to groups a) control, b) low TRP diet, c) low TRP diet+paroxetine and d) low TRP diet+vortioxetine. Vortioxetine was administered via the diet (0.76mg/kg of food weight) and paroxetine via drinking water (10mg/kg/day) for 14days. Both drugs resulted in SERT occupancies >90%...
August 10, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28800937/vortioxetine-a-new-alternative-for-the-treatment-of-major-depressive-disorder
#6
Estela Salagre, Iria Grande, Brisa Solé, Jose Sanchez-Moreno, Eduard Vieta
Major Depressive Disorder (MDD) is a serious psychiatric condition. Its treatment remains a challenge nowadays. Vortioxetine is a novel antidepressant with a unique profile, as it acts as a multimodal serotoninergic agent. Its efficacy in MDD has been established in many short- and long-term studies, with 7 positive, 4 negative and 1 failed randomized controlled trials. Moreover, its ability to modulate a wide range of neurotransmitters (serotonin, dopamine, norepinephrine, histamine, glutamate or GABA) confers vortioxetine pro-cognitive effects...
August 8, 2017: Revista de Psiquiatrí́a y Salud Mental
https://www.readbyqxmd.com/read/28707591/new-generation-non-ssri-antidepressants-therapeutic-drug-monitoring-and-pharmacological-interactions-part-1-snris-smss-saris
#7
Roberto Mandrioli, Michele Protti, Laura Mercolini
BACKGROUND: New-generation antidepressants (NGAs) are the latest additions to the clinician's arsenal in the fight against depression. After the introduction of selective serotonin reuptake inhibitors (SSRIs), a plethora of other groups followed, identified by their main mechanisms of activity: serotonin and norepinephrine reuptake inhibitors (SNRI); serotonin modulators and stimulators (SMS); serotonin antagonists and reuptake inhibitors (SARI); noradrenergic and selective serotonergic antidepressants (NaSSA); norepinephrine reuptake inhibitors (NeRI); serotonin, norepinephrine and dopamine reuptake inhibitors (SNDRI) or triple reuptake inhibitors (TRI); and melatonin and serotonin agonists (MaSA)...
July 12, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28693903/effectiveness-of-long-term-vortioxetine-treatment-of-patients-with-major-depressive-disorder
#8
Eduard Vieta, Henrik Loft, Ioana Florea
To investigate the effectiveness, safety, and tolerability of vortioxetine in patients treated at therapeutic doses (5-20mg/day) for both acute and maintenance treatment, patient-level data were pooled from 5 long-term (52-week), open-label extension studies of major depressive disorder. The mean (±standard deviation) MADRS total score improved from 17.1±10.2 at the start of maintenance therapy to 7.6±8.2 (observed cases [OC]) or 10.3±9.9 (last observation carried forward [LOCF]) at week 52. The mean HAM-A total scores improved from 11...
July 7, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28692076/-full-functional-recovery-in-depression-treatment-clinical-cases-treated-with-vortioxetina
#9
Felicia Russo
Depression is one of the most common diseases worldwide, with more than 350 million people affected. Although many patients initially show a good response to antidepressant therapy, they tend to suffer from residual symptoms that affect their social, cognitive, physical and psychological domains. Residual symptoms severely impact the patient's global functioning and quality of life and increase the risk of recurrence. In the last few years, pharmacological research has focused on drugs able to mitigate the severity of depressive symptoms and to control persistent cognitive and functional disabilities...
May 2017: Rivista di Psichiatria
https://www.readbyqxmd.com/read/28677828/vortioxetine-for-depression-in-adults
#10
REVIEW
Markus Koesters, Giovanni Ostuzzi, Giuseppe Guaiana, Johanna Breilmann, Corrado Barbui
BACKGROUND: Major depressive disorder is a common mental disorder affecting a person's mind, behaviour and body. It is expressed as a variety of symptoms and is associated with substantial impairment. Despite a range of pharmacological and non-pharmacological treatment options, there is still room for improvement of the pharmacological treatment of depression in terms of efficacy and tolerability. The latest available antidepressant is vortioxetine. It is assumed that vortioxetine's antidepressant action is related to a direct modulation of serotonergic receptor activity and inhibition of the serotonin transporter...
July 5, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28663124/comparative-evaluation-of-vortioxetine-as-a-switch-therapy-in-patients-with-major-depressive-disorder
#11
Michael E Thase, Natalya Danchenko, Melanie Brignone, Ioana Florea, Francoise Diamand, Paula L Jacobsen, Eduard Vieta
Switching antidepressant therapy is a recommended strategy for depressed patients who neither respond to nor tolerate an initial pharmacotherapy course. This paper reviews the efficacy and tolerability of switching to vortioxetine. All three published studies of patients with major depressive disorder (MDD) switched from SSRI/SNRI therapy to vortioxetine due to lack of efficacy or tolerability were selected. Vortioxetine was evaluated versus agomelatine directly (REVIVE) and versus sertraline, venlafaxine, bupropion, and citalopram in an indirect treatment comparison (ITC) from switch studies retrieved in a literature review...
August 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28651185/treatment-of-neurocognitive-symptoms-in-unipolar-depression-a-systematic-review-and-future-perspectives
#12
REVIEW
E Salagre, B Solé, Y Tomioka, B S Fernandes, D Hidalgo-Mazzei, M Garriga, E Jimenez, J Sanchez-Moreno, E Vieta, I Grande
BACKGROUND: Cognitive symptoms in Major Depressive Disorder (MDD) are persistent and commonly entail neurocognitive impairment and a decline in quality of life. This systematic review gathers the current scientific evidence on therapeutic strategies for neuropsychological impairment in MDD. METHOD: A systematic search on PubMed, PsycINFO and Clinicaltrials.gov was carried out on December 2016 according to PRISMA using Boolean terms to identify interventions for the treatment of cognitive dysfunction in MDD...
October 15, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28535081/advances-in-antidepressants-for-treating-post-stroke-depression
#13
REVIEW
Stefano Paolucci
Post-stroke depression (PSD) is a common and serious complication after stroke, occurring in nearly one third of stroke survivors, and affecting mortality rate, functional outcome, rehabilitation results and quality of life. However, in the common clinical practice only a minority of patients are properly treated. A relatively small number of scientific reports are available on clinical usefulness and safety of antidepressants (ADs) in PSD. Areas covered: This report provides an updated review about pharmacological state of art of PSD, including efficacy and safety of different drugs and their role on prevention, treatment and functional outcome...
July 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28533517/vortioxetine-reduces-bold-signal-during-performance-of-the-n-back-working-memory-task-a-randomised-neuroimaging-trial-in-remitted-depressed-patients-and-healthy-controls
#14
J Smith, M Browning, S Conen, R Smallman, J Buchbjerg, K G Larsen, C K Olsen, S R Christensen, G R Dawson, J F Deakin, P Hawkins, R Morris, G Goodwin, C J Harmer
Cognitive dysfunction is common in depression during both acute episodes and remission. Vortioxetine is a novel multimodal antidepressant that has improved cognitive function including executive function in depressed patients in randomised placebo-controlled clinical trials. However, it is unclear whether vortioxetine is able to target directly the neural circuitry implicated in the cognitive deficits in depression. Remitted depressed (n=48) and healthy volunteers (n=48) were randomised to receive 14 days treatment with 20 mg vortioxetine or placebo in a double-blind design...
May 23, 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/28531820/adverse-effects-and-treatment-satisfaction-among-online-users-of-four-antidepressants
#15
Shannon Hughes, Jeffrey Lacasse, Reid Rogers Fuller, Jennifer Spaulding-Givens
Adverse effects (AEs) are an important factor in antidepressant treatment decision-making, though common AE profiles from clinical trial research highlight physical AEs to the neglect of emotional and behavioral AEs. First-hand accounts of antidepressant users on the Internet can supplement AE profiles with information gained from real-world treatment experiences. We examined online user reviews of two older (escitalopram; duloxetine) and two newer (vilazodone; vortioxetine) antidepressants for differences in their AE profiles and determined which categories of AEs were associated with users' satisfaction...
September 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28499187/vortioxetine-a-review-of-the-pharmacology-and-clinical-profile-of-the-novel-antidepressant
#16
REVIEW
Magdalena Sowa-Kućma, Patrycja Pańczyszyn-Trzewik, Paulina Misztak, Rafał R Jaeschke, Katherine Sendek, Krzysztof Styczeń, Wojciech Datka, Magdalena Koperny
The aim of this paper was to review the up-to-date evidence base on pharmacology and clinical properties of vortioxetine. Vortioxetine is a novel antidepressant, approved by the US Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD). Because vortioxetine exhibits both an antidepressant and anxiolytic effect, it may be effective in treating both depressive and anxiety disorders, such as generalized anxiety disorder (GAD). Based on its pharmacodynamics profile and preclinical studies, it is believe that the drug's clinical action is mediated mainly by selective blockade of serotonin reuptake (by inhibiting the serotonin transporter [SERT]) and direct modulation of 5-HT receptors activity (such as 5-HT3, 5-HT7, 5-HT1D and 5-HT1B)...
February 1, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/28414050/a-study-of-time-and-sex-dependent-effects-of-vortioxetine-on-rat-sexual-behavior-possible-roles-of-direct-receptor-modulation
#17
Yan Li, Alan L Pehrson, Ronald S Oosting, Maria Gulinello, Berend Olivier, Connie Sanchez
Treatment-related sexual dysfunction is a common side effect of antidepressants and contributes to patient non-compliance or treatment cessation. However, the multimodal antidepressant, vortioxetine, demonstrates low sexual side effects in depressed patients. To investigate the mechanisms involved, sexual behavior was assessed in male and female rats after acute, and repeated (7 and 14 days) treatment with vortioxetine, flesinoxan (a 5-HT1A receptor agonist), CP-94253 (a 5-HT1B receptor agonist), or ondansetron (a 5-HT3 receptor antagonist)...
July 15, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28408985/new-drugs-in-psychiatry-focus-on-new-pharmacological-targets
#18
REVIEW
Filippo Caraci, Gian Marco Leggio, Salvatore Salomone, Filippo Drago
The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer's disease...
2017: F1000Research
https://www.readbyqxmd.com/read/28407315/drugs-with-antidepressant-properties-affect-tryptophan-metabolites-differently-in-rodent-models-with-depression-like-behavior
#19
Amanda Eskelund, Yan Li, David P Budac, Heidi K Müller, Maria Gulinello, Connie Sanchez, Gregers Wegener
The metabolism of tryptophan through kynurenine and serotonin pathways is linked to depression. Here, effects of different drugs with antidepressant properties (vortioxetine, fluoxetine, and ketamine) on various tryptophan metabolites in different brain regions and plasma were examined using tandem mass spectrometry (LC-MS/MS), in Flinders Sensitive Line rats, a genetic rat model of depression, and its controls: Flinders Sensitive Line and Sprague-Dawley rats. Protein levels of kynurenine pathway enzymes were measured in the brains and livers of these rat strains...
July 2017: Journal of Neurochemistry
https://www.readbyqxmd.com/read/28366617/acute-dosing-of-vortioxetine-strengthens-event-related-brain-activity-associated-with-engagement-of-attention-and-cognitive-functioning-in-rats
#20
Bettina Laursen, Cecilie H Bundgaard, Carina Graversen, Morten Grupe, Connie Sanchez, Steven C Leiser, Helge B D Sorensen, Asbjørn M Drewes, Jesper F Bastlund
Studies of the antidepressant vortioxetine have demonstrated beneficial effects on cognitive dysfunction associated with depression. To elucidate how vortioxetine modulates neuronal activity during cognitive processing we investigated the effects of vortioxetine (3 and 10 mg/kg) in rats performing an auditory oddball (deviant target) task. We investigated neuronal activity in target vs non-target tone responses in vehicle-treated animals using electroencephalographic (EEG) recordings. Furthermore, we characterized task performance and EEG changes in target tone responses of vortioxetine vs controls...
March 30, 2017: Brain Research
keyword
keyword
22035
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"